ImmuCell (ICCC) President and CEO Olivier Buys $76K of Stock
ICCC's CEO Paul Te Boekhorst purchased 8,000 shares, boosting his stake in the company.
Reviewed by automated data checks against the source filing. How we make and check alerts
Te Boekhorst Paul Francis Olivier, President and CEO at ImmuCell Corporation ($ICCC), bought 8,000 shares at an average price of $9.50, worth about $76,000, on June 18, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $ICCC is up 4.2% after 1 week, up 17.5% after 1 month and up 13.3% to date (from the $9.49 close on Jun 18, 2026).
ICCC
ImmuCell Corporation
Key Points
- On June 18, 2026, ICCC's CEO Paul Te Boekhorst bought 8,000 shares at $9.50 each, totaling $76,000.
- Shares of ICCC traded near $9.49 on Monday, with significant institutional activity from major funds.
- Vanguard Capital opened a new ICCC position, while Morgan Stanley increased its stake by 77.8%.
Get $ICCC trade alerts by text
We text you when insiders, Congress or big funds trade $ICCC. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated ImmuCell Corporation alert may contain errors. Disclosures
ICCC's President and CEO, Paul Te Boekhorst, has increased his investment in the company by buying 8,000 shares. The purchase, made on June 18, 2026, was at an average price of $9.50 per share, totaling $76,000. This transaction was not part of a pre-planned trading program.
Insider Buying and Selling at ImmuCell Corporation
Paul Te Boekhorst, ICCC's President and CEO, bought 8,000 shares on June 18, 2026, at $9.50 per share, marking a personal investment of $76,000. This purchase was not made under a Rule 10b5-1 trading plan. Other recent insider transactions include David Scott Tomsche, Paul Wainman, Kathy Turner, and Gloria Basse, each acquiring shares on April 15, 2026.
Other Institutional Activity in ICCC
Institutional investors have been active in ICCC. Vanguard Capital Management LLC opened a new position with 260,327 shares valued at approximately $1,647,870. Morgan Stanley increased its holdings by 97,000 shares, a 77.8% increase, bringing its total to 221,716 shares worth about $1,403,462. Renaissance Technologies LLC added 1,100 shares, a 0.7% increase, to reach 151,789 shares valued at $960,824. Meanwhile, Cresset Asset Management, LLC and Bleichroeder LP maintained their positions without change, and Geode Capital Management, LLC reduced its stake by 6,492 shares, a 9.0% decrease, ending with 65,765 shares.
ImmuCell Corporation Stock Down 4.6%
Shares of ICCC traded near $9.49 on Monday. The stock has seen significant activity from both insiders and institutional investors, indicating ongoing interest and investment. Institutional movements and insider transactions often provide insights into a company's potential future performance.
Bottom Line
Paul Te Boekhorst's recent purchase of ICCC shares underscores his confidence in the company's future. Insider buying is often watched closely by investors as a potential signal of a company's prospects. Institutional activity also highlights interest in ICCC, with major funds like Vanguard Capital and Morgan Stanley adjusting their positions. As always, remember that these insider and institutional reports reflect past actions and may not indicate current positions.
Related Filing Alerts
Source: Te Boekhorst Paul Francis Olivier's Form 4 filing on $ICCC (Jun 18, 2026). Find the original filing: ICCC Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts